Details of the Drug
General Information of Drug (ID: DMFQI4C)
Drug Name |
2-(4-chlorophenyl)-4,5-dihydro-1H-imidazole
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
2-(4-chlorophenyl)-4,5-dihydro-1H-imidazole; 13623-52-4; CHEMBL448710; 1H-Imidazole,2-(4-chlorophenyl)-4,5-dihydro-; NSC129258; AC1L5PGD; AC1Q3R0Q; AC1Q3IU9; 1h-imidazole, 2-(4-chlorophenyl)-4,5-dihydro-; SCHEMBL523059; CTK4C0220; DTXSID90299300; XUMWMBLBTZAVLW-UHFFFAOYSA-N; MolPort-005-311-522; ZINC608390; 2-(4-chlorophenyl)-2-imidazoline; 2-(4-Chlorophenyl)-1-imidazoline; BDBM50266028; STK367850; AKOS005444786; NE32890; NSC-129258; MCULE-4125153952; 2-Imidazoline, 2-(p-chloro-phenyl)-; DB-063124; FT-0766187; EN300-29599
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 180.63 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 1.5 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 1 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||